Hideyo Noguchi Africa Prize
Awardees: Brian Greenwood and Miriam K. Were
The Japanese Government has established the Hideyo Noguchi Africa Prize in July 2006 to award individuals with outstanding achievements in the field of medical research and health services. Africa is a region with a serious need for solutions to medical and health challenges. The prize aims to encourage the fight against diseases in Africa, thus contributing to the health and welfare of people living in Africa and elsewhere.
The Government of Japan announced on 26 March 2008 its decision to award the inaugural Hideyo Noguchi Africa Prizes to Brian Greenwood for Medical Research and Miriam K. Were for Medical Services. The laureates of each category will be awarded a citation, a medal and an honorarium of 100 million yen (approximately 1 million US dollars) at the award ceremony on 28 May 2008 at the Fourth Tokyo International Conference on African Development (TICAD IIV) in Yokohama, Japan.
Brian Greenwood: born 1938 in the UK; British citizen; MD 1968 University of Cambridge, UK; Manson Professor of Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, UK The Hideyo Noguchi Africa Prize for medical research is awarded to Brian Greenwood for his bold and innovative work on malaria. At a time when malaria was spreading uncontrollably across the African continent claiming more than 1 million lives a year, Greenwood contributed to creation and designing of effective strategies to control malaria. His crucial contributions in malaria research greatly helped developing the tools and knowledge that are essential in turning the tide on this terrible disease. His work brings hope where very recently only despair existed.
Pioneering field research on malaria
Dr. Greenwood has spent more than 30 years on site in Africa including 15 years as Director of the MRC Laboratories in the Gambia where he pioneered landmark research contributing to the understanding of the immunology, pathogenesis and epidemiology of malaria, a major killer in Africa, and other infectious diseases such as meningitis and pneumonia, all major contributors to mortality among children in Africa. His research and transnational clinical studies, involving simple but high quality methods as well as field trials of drugs and vaccines, have provided the scientific underpinning to a wide range of influential public health policies at national and international levels. His important contributions include:
- Demonstration of the effectiveness of insecticide-treated nets for control of malaria, which is now the cornerstone of malaria interventions throughout the continent, supported and financed by many donor agencies
- Primary studies on artemisinin-based combination therapies (ACTs), now widely adapted as first-line treatment for malaria
- Demonstration that malaria chemoprevention reduces child mortality. This is now being applied for intermittent preventive treatment in infants, children and in pregnancy
- Substantial contributions to trials of malaria vaccines, including the efficacious RTS, S vaccine
- Demonstration of how Haemophilus influenzae type b (Hib) infection can be eliminated by vaccination
- Large-scale clinical trials showing the potential for reducing child morbidity and mortality through use of pneumococcal conjugate vaccines
- Substantial contributions to the development of meningococcal vaccines. To learn more...
Miriam K. Were: born 1940 in Kenya; Kenyan citizen; Doctor of Public Health, Health Planning and Management 1981, Johns Hopkins University, USA; Co-founder and Health Specialist UZIMA Foundation, Kenya.
The Hideyo Noguchi Africa Prize for medical services is awarded to Miriam K. Were, whose efforts to bring basic medical services and health rights to women and children in the villages of East Africa has been a beacon of hope for millions of people in Africa and the world. Through her work with African Medical and Research Foundation (AMREF) and UZIMA Foundation, Were has been a source of inspiration for all people on the African continent.
Community-based approach to heal th service
For the past 40 years, Were has dedicated her life to advancing the health and welfare of the people of Africa through a focus on the practicalities of delivering service at a local level. She has united communities to develop and implement innovative solutions to quotidian health problems. The most illustrious example of her community-based approach is her ongoing work to build public toilet facilities in local communities, improving hygiene and overcoming longstanding taboos. She also drastically raised the infant vaccination rate by organizing children into small groups to visit local clinics. Her innovation and systemic precedents have had enduring impacts not only in Kenya but throughout the East African region and across the entire continent, through her engagement with the African Union and as a key health advisor to the African Heads of State on AIDS, Tuberculosis and Malaria
On-going bat t le against HIV/AIDS
Her style of work through the direct engagement of the youth, sex workers, intravenous drug users, homosexuals and others to encourage openness and frank discussion on sexuality and HIV/AIDS has galvanized communities in Kenya and contributed to the reduction of stigma and discrimination against people living with HIV/AIDS. She is a dedicated advocate for vulnerable populations, especially the poor and the marginalized. She is also committed to the empowerment and development of all voices across lines of sex, tribe, and age and class background. Widows and orphans severely affected by HIV/AIDS are amongst those most positively touched by her contribution to expanding access to medical services.
As the Chairperson of Kenya’s National AIDS Control Council, Were has provided strong leadership and orchestrated a balanced HIV/AIDS response agenda that has enabled Kenya to consistently register a reduction of HIV prevalence and AIDS-related mortality. Between 2002 and 2006, HIV prevalence in Kenya was reduced from 13 percent to 5.1 percent. By 2007, the country had 150,000 people on ARV drugs compared to 2,000 in 2002. Throughout, Were has stressed the role that people living with HIV and AIDS can play in the prevention, management and socio-mitigation of the AIDS pandemic. To learn more...